Research aarkstore enterprise immunology partnering terms and agreements
Respiratory Partnering Terms and Agreements
1. Respiratory Partnering Terms and Agreements
Report Details:
Published:September 2012
No. of Pages: 754
Price: Single User License – US$2695
This report provides comprehensive understanding and unprecedented access to the respiratory
partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter
respiratory partnering deals. The majority of deals are discovery or development stage whereby
the licensee obtains a right or an option right to license the licensors respiratory technology. These
deals tend to be multicomponent, starting with collaborative R&D, and commercialization of
outcomes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical
insight into the negotiation process in terms of what you can expect to achieve during the
negotiation of terms. Whilst many smaller companies will be seeking details of the payments
clauses, the devil is in the detail in terms of how payments are triggered – contract documents
provide this insight where press releases do not.
This report contains over 1,000 links to online copies of actual respiratory deals and contract
documents as submitted to the Securities Exchange Commission by companies and their
partners. Contract documents provide the answers to numerous questions about a prospective
partner’s flexibility on a wide range of important issues, many of which will have a significant
impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of respiratory dealmaking and business
activities. Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in respiratory dealmaking since 2007 covering trends
by year, deal type, stage of development, technology type and therapeutic indication. In addition
the chapter includes an analysis of financial deal terms by stage at signing covering headline
value, upfront payment, milestone payments and royalty rates. Analysis includes median values
and distribution of values for each stage of development.
Chapter 3 provides a review of the leading respiratory deals since 2007. Deals are listed by
headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma
companies. Where the deal has an agreement contract published at the SEC a link provides
online access to the contract.
Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief
summary followed by a comprehensive listing of respiratory deals, as well as contract documents
available in the public domain. Where available, each deal title links via Weblink to an online
2. version of the actual contract document, providing easy access to each contract document on
demand.
Chapter 5 provides comprehensive access to all respiratory deals since 2007 where a deal
contract is available, providing the user with direct access to contracts as filed with the SEC
regulatory authorities. Each deal title links via Weblink to an online version of the deal record
contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all respiratory partnering deals signed and
announced since 2007. The chapter is organized by specific respiratory therapy focus. Each deal
title links via Weblink to an online version of the deal record and where available, the contract
document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all respiratory partnering
deals signed and announced since 2007. The appendices are organized by company A-Z, stage
of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and
technology type. Each deal title links via Weblink to an online version of the deal record and where
available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in
respiratory partnering and dealmaking since 2007.
In conclusion, this report provides everything a prospective dealmaker needs to know about
partnering in the research, development and commercialization of respiratory technologies and
products.
Respiratory Partnering Terms and Agreements provides the reader with the following key
benefits:
•In-depth understanding of respiratory deal trends since 2007
•Access respiratory deal headline, upfront, milestone and royalty data
•Research hundreds of actual contracts between respiratory partner companies
•Comprehensive access to over 1,000 links to actual respiratory deals entered into by the world’s
biopharma companies
•Indepth review of respiratory deals entered into by the leading fifty bigpharma companies
•Benchmark the key deal terms companies have agreed in previous deals
•Identify key terms under which companies partner respiratory opportunities
•Uncover companies actively partnering respiratory opportunities
Get your copy of this report @
http://www.reportsnreports.com/reports/191588-respiratory-partnering-terms-and-agreements.html
Major points covered in Table of Contents of this report include
Table of Contents
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in central nervous system dealmaking
2.1. Introduction
2.2. Central nervous system partnering over the years
3. 2.3. Bigpharma central nervous system dealmaking activity
2.4. Bigpharma not active in Central nervous system
2.5. Central nervous system partnering by deal type
2.6. Central nervous system partnering by industry sector
2.7. Central nervous system partnering by stage of development
2.8. Central nervous system partnering by technology type
2.9. Central nervous system partnering by CNS indication
2.10. Average deal terms for central nervous system
2.10.1 Central nervous system headline values
2.10.2 Central nervous system upfront payments
2.10.3 Central nervous system milestone payments
2.10.4 Central nervous system royalty rates
Chapter 3 – Leading central nervous system deals
3.1. Introduction
3.2. Top central nervous system deals by value
3.3. Top central nervous system deals involving bigpharma
Chapter 4 – Bigpharma central nervous system deals
4.1. Introduction
4.2. How to use bigpharma partnering deals
4.3. Bigpharma central nervous system partnering company profiles
Abbott
Actavis
Allergan
Amgen
Aspen Pharmacare
Astellas
AstraZeneca
Baxter International
Bayer
Bayer Healthcare
Bayer Schering Pharma
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
CSL
Daiichi Sankyo
Dainippon Sumitomo
Dainippon Pharmaceutical
Eisai
Eli Lilly
Endo Pharmaceuticals
Forest Laboratories
4. Forest Laboratories Ireland
GlaxoSmithKline
Hospira
Johnson & Johnson
Kyowa Hakko Kirin
Lundbeck
Merck & Co
Merck KGaA
Mylan
Novartis
Otsuka
Pfizer
Purdue
Roche
Genentech
Sanofi
Servier
Shionogi
Shire
Takeda
Teva
UCB
Valeant
Watson
Chapter 5 – Central nervous system partnering contracts directory
5.1. Introduction
5.2. By deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
Development
Distribution
Equity purchase
Grant
Interests
Joint venture
Licensing
6. In vitro models
Natural product
Oligonucleotide
Orphan drug
Peptides
Processes
Proteomics
Radio/Chemo-therapy
Recombinant DNA
Research services
Research supplies
RNA therapeutics
Screening
Small molecules
Vaccines
Chapter 6 – Central nervous system dealmaking by indication
6.1. Introduction
6.2. Deals by therapeutic indication
Central Nervous System
Cerebral palsy
Creutzfeldt Jakob disease
Dizziness
Epilepsy
Guillain Barre syndrome
Headache
Meningitis
Bacterial
Haemophilus influenzae Type B
Meningococcal
Mycobacterium tuberculosis
Pneumococcal
Fungal
Viral
Migraine
Motor Neurone Disease (Amyotrophic Lateral Sclerosis/Lou Gehrig's Disease)
Multiple sclerosis
Nausea
Neuropathy
Pain
Neuralgia
Paralysis
Parkinson's disease
7. Restless leg syndrome
Spinal cord
Stroke
Traumatic Brain Injury
Vertigo
Weakness
Chapter 7 – Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form – Reports
Order Form – Therapy Reports
Appendices
Appendix 1 – Directory of central nervous system deals by company A-Z 2007-2012
Appendix 2 – Directory of central nervous deals by deal type 2007-2012
Appendix 3 – Directory of central nervous system deals by stage of development 2007-2012
Appendix 4 – Directory of central nervous system deals by technology type 2007-2012
Appendix 5 – Deal type definitions
List of Figures
Figure 1: Central nervous system partnering since 2007
Figure 2: Bigpharma – top 50 – Central nervous system deals 2007 to 2012
Figure 3: Bigpharma Central nervous system deal frequency – 2007 to 2012
Figure 4: Inactive bigpharma in CNS 2007-2012
Figure 5: Central nervous system partnering by deal type since 2007
Figure 6: Central nervous system partnering by industry sector since 2007
Figure 7: Central nervous system partnering by stage of development since 2007
Figure 8: Central nervous system partnering by technology type since 2007
Figure 9: Central nervous system partnering by CNS target since 2007
Figure 10: Central nervous system deals with a headline value
Figure 11: Central nervous system deal headline value distribution, US$million – discovery stage
Figure 12: Central nervous system deal headline value distribution, US$million – preclinical stage
Figure 13: Central nervous system deal headline value distribution, US$million – phase I stage
Figure 14: Central nervous system deal headline value distribution, US$million – phase II stage
Figure 15: Central nervous system deal headline value distribution, US$million – phase III stage
Figure 16: Central nervous system deal headline value distribution, US$million – regulatory stage
Figure 17: Central nervous system deal headline value distribution, US$million – marketed stage
Figure 18: Summary median headline value by stage of development, 2007-2012
Figure 19 Central nervous system deals with upfront payment values
8. Figure 20: Central nervous system deal upfront payment distribution, US$million – discovery stage
Figure 21: Central nervous system deal upfront payment distribution, US$million – preclinical
stage
Figure 22: Central nervous system deal upfront payment distribution, US$million – phase I stage
Figure 23: Central nervous system deal upfront payment distribution, US$million – phase II stage
Figure 24: Central nervous system deal upfront payment distribution, US$million – phase III stage
Figure 25: Central nervous system deal upfront payment distribution, US$million – regulatory
stage
Figure 26: Central nervous system deal upfront payment distribution, US$million – marketed stage
Figure 27: Summary median upfront payments by stage of development, 2007-2012
Figure 28: Central nervous system deals with milestone payments
Figure 29: Central nervous system deal milestone distribution, US$million – discovery stage
Figure 30: Central nervous system deal milestone distribution, US$million – preclinical stage
Figure 31: Central nervous system deal milestone distribution, US$million – phase I stage
Figure 32: Central nervous system deal milestone distribution, US$million – phase II stage
Figure 33: Central nervous system deal milestone distribution, US$million – phase III stage
Figure 34: Central nervous system deal milestone distribution, US$million – regulatory stage
Figure 35: Central nervous system deal milestone distribution, US$million – marketed stage
Figure 36: Central nervous system deals with royalty rates, %
Figure 37: Central nervous system deal royalty rate distribution, US$million – discovery stage
Figure 38: Central nervous system deal royalty rate distribution, US$million – preclinical stage
Figure 39: Central nervous system deal royalty rate distribution, US$million – phase I stage
Figure 40: Central nervous system deal royalty rate distribution, US$million – phase II stage
Figure 41: Central nervous system deal royalty rate distribution, US$million – phase III stage
Figure 42: Central nervous system deal royalty rate distribution, US$million – regulatory stage
Figure 44: Summary median royalty rate by stage of development, 2007-2012
Figure 45: Top central nervous system deals by value since 2007
Figure 46: Top central nervous system deals signed by bigpharma value since 2007
Figure 47: Online partnering resources
Figure 48: Forthcoming partnering events
Contact: sales@reportsandreports.com for more information.
